Back to Journals » OncoTargets and Therapy » Volume 15

LncRNA GA-Binding Protein Transcription Factor Subunit Beta-1 Antisense RNA 1 Inhibits Renal Carcinoma Growth Through an MiR-1246/Phosphoenolpyruvate Carboxykinase 1 Pathway [Retraction]

Authors Gao S, Zhang F, Sun H , Yang X

Received 14 January 2022

Accepted for publication 14 January 2022

Published 20 January 2022 Volume 2022:15 Pages 83—84

DOI https://doi.org/10.2147/OTT.S358437



Gao S, Zhang F, Sun H, Yang X. Onco Targets Ther. 2020;13:6827–6836.

The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 2 and 4. Specifically:

  • Figure 2D, panel 786-o Ad-Vector appears to have been duplicated with Figure 4D, panel 786-0 GABPB1-AS1+siPCK1.
  • Figure 2D, panel 786-o Ad-GABPB1-AS1 appears to have been duplicated with Figure 4D, panel GABPB1-AS1.
  • Figure 4D, panel GABPB1-AS1+siPCK1 appears to have been duplicated with Figure 4E, panel caki-1 Vector.

The authors responded to our queries but were unable to provide a satisfactory explanation for the alleged duplication or adequate raw data relating to the study. The Editor determined the findings of the study were invalid and requested for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

This retraction relates to this paper

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.